Skip to main content
Premium Trial:

Request an Annual Quote

Thomas Lengauer

Thomas Lengauer, director at the Max Planck Institute for Informatics in Saarbrücken, has been elected as the next president of the International Society for Computational Biology (ISCB). He will take office as president-elect of the ISCB in January 2017 and will officially become president of the society in January 2018 taking over from current ISCB president Alfonso Valencia. Lengauer's term will end in January 2021. Lengauer will be the seventh president of the ISCB. He is a founding member of the society and currently serves as its vice president. He was named an ISCB fellow in 2015. He holds two doctoral degrees, one in mathematics from the Free University of Berlin, and one in computer science from Stanford University. His research interests lie in the field computational epigenomics, specifically, in understanding viral drug resistance. His lab has developed software that is used to select drug combinations for HIV patients.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.